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Abstract
Background: Hormone therapy plus radiotherapy significantly decreases recurrences and mortality of patients
affected by locally advanced prostate cancer. In order to determine if difference exists according to the hormonal
treatment duration, a literature-based meta-analysis was performed.
Methods: Relative risks (RR) were derived through a random-effect model. Differences in primary (biochemical
failure, BF; cancer-specific survival, CSS), and secondary outcomes (overall survival, OS; local or distant recurrence,
LR/DM) were explored. Absolute differences (AD) and the number needed to treat (NNT) were calculated.
Heterogeneity, a meta-regression for clinic-pathological predictors and a correlation test for surrogates were
conducted.
Results: Five trials (3,424 patients) were included. Patient population ranged from 267 to 1,521 patients. The longer
hormonal treatment significantly improves BF (with significant heterogeneity) with an absolute benefit of 10.1%,
and a non significant trend in CSS. With regard to secondary end-points, the longer hormonal treatment
significantly decrease both the LR and the DM with an absolute difference of 11.7% and 11.5%. Any significant
difference in OS was observed. None of the three identified clinico-pathological predictors (median PSA, range
9.5-20.35, Gleason score 7-10, 27-55% patients/trial, and T3-4, 13-77% patients/trial), did significantly affect
outcomes. At the meta-regression analysis a significant correlation between the overall treatment benefit in BF,
CSS, OS, LR and DM, and the length of the treatment was found (p≤0.03).
Conclusions: Although with significant heterogeneity (reflecting different patient’ risk stratifications), a longer
hormonal treatment duration significantly decreases biochemical, local and distant recurrences, with a trend for
longer cancer specific survival.
Background
Androgen-deprivation remains the cornerstone of treat-
ment for patients with hormone-sensitive advanced pros-
tate cancer [1]. The combination of hormonal suppression
and the radiotherapy is able to significantly decrease the
recurrences and the mortality of patients affected by
locally advanced prostate cancer. Substantial toxicities
were also identified when hormone therapy was used.
[2-11]. A recently conducted meta-analysis has demon-
strated an overall absolute benefit of 7.5-10% in favor of
the addition of the hormone therapy to in terms of bio-
chemical failure and clinical progression free survival [12].
The optimal duration of androgen ablation therapy is
still controversial despite a growing number of prognos-
tic factors that have been shown to predict disease
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outcome [13]. In all prospective randomized trials, long
term hormonal therapy (more than 2 years) improves
survival in patients with locally high risk (Gleason score
≥ 8, median PSA ≥ 20, stage ≥ T3) advanced prostate
cancer. This strategy, however, is also associated with an
increased risk of morbidities, such as osteoporosis, dia-
betes, depression, dislipidemia and abdominal obesity
[14,15].
The value of short-term hormonal treatment in
patients with intermediate risk disease (Gleason score ≥
7, median PSA ≥ 10, stage ≥ T2c) has also been detected
[16,17], although its role in high-risk disease is still con-
troversial. Nevertheless, short courses of hormonal
suppression have been shown to be very effective in
downstaging localized disease. Surgical series have pro-
vided some histopathological confirmation, with signifi-
cant decreases in margin-positive rates in prostatectomy
after neoadjuvant hormonal therapy [18,19].
In order to determine if difference exists between a
shorter and a longer hormone therapy (HT) in combina-
tion with radiotherapy, a literature based meta-analysis
was conducted.
Methods
The analysis was conducted following 4 steps: definition
of the outcomes (definition of the question the analysis
was designed to answer), definition of the trial selection
criteria, definition of the search strategy, and a detailed
description of the statistical methods used [20,21].
Outcome definition
The combination of a short-term HT (ST) and RT was
considered as the experimental arm and a long-term
HT (LT) and RT as the standard comparator. Analysis
was conducted in order to find significant differences in
primary and secondary outcomes, according to a pre-
viously published meta-analysis and the reported
sequence and definitions in the selected trials. Primary
outcomes for the magnitude of the benefit analysis were
both the Biochemical Failure (BF, time between rando-
mization and PSA increase) and the CSS (time between
randomization and death for prostate cancer). Secondary
end-points were: OS (time between randomization and
death for any cause), local failure rate (LF) and distant
metastases rate (DM).
Search strategy
Deadline for trial publication and/or presentation was
September 30th, 2010. Updates of Randomized Clinical
Trials (RCTs) were gathered through Medline (PubMed:
http://www.ncbi.nlm.nih.gov/PubMed), ASCO (American
Society of Clinical Oncology, http://www.asco.org),
ESMO (European Society for Medical Oncology, http://
www.esmo.org), FECS (Federation of European Cancer
Societies, http://www.fecs.be), and ASTRO (American
Society for Therapeutic Radiology and Oncology, http://
www.astro.org) website searches. Key-words used for
searching were: adjuvant hormone therapy, prostate
cancer, radiotherapy, duration, longer, shorter, review,
metanalysis, meta-analysis, pooled analysis, randomized,
phase III, comprehensive review, systematic review. In
addition to computer browsing, review and original papers
were also scanned in the reference section to look for
missing trials. Furthermore, lectures at major meetings
(ASCO, ESMO, ECCO, and ASTRO) having ‘hormone
treatment and radiotherapy for prostate cancer’ as the
topic were checked. No language restrictions were applied.
Trial identification criteria
All prospective phase III RCTs published in peer-
reviewed journals or presented at the ASCO, ECCO,
ESMO and ASTRO meetings until September 2010,
in which previously untreated patients with locally
advanced prostate cancer were prospectively randomized
to short or long-HT plus radiotherapy were gathered.
Any trial exploring a shorter versus a longer HT
(regardless of their absolute values) in combination with
RT for the treatment of LAPC was considered eligible.
Data extraction
The number of events for primary and secondary end-
points were extracted; the last trial’s available update
was considered as the original source. All data were
reviewed and separately computed by five investigators
(F.Cu., E.B., D.G., I.S., and P.C.).
Data synthesis
The log of relative risk ratio (RR) was estimated for each
considered endpoint [22], and 95% Confidence Intervals
(CI) were derived [23]. A random-effect model accord-
ing to the DerSimonian method was preferred to the
fixed, given the known clinical heterogeneity of trials
[24-26]; a Q-statistic heterogeneity test was used
[27-29]. Absolute benefits for each outcome were calcu-
lated (i.e. absolute benefit=exp {RR × log[control survi-
val]} - control survival [30]; modified by Parmar and
Machin [31]). The number of patients needed to be
treated for one single beneficial patient was determined
(NNT: 1/[(Absolute Benefit)/100]) [32]. Results were
depicted in all figures as conventional meta-analysis for-
est plots; a RR <1.0 indicates fewer events in the experi-
mental arm. In order to find possible correlations
between outcome effect and negative prognostic factors
(selected among trials’ reported factors: the median
PSA, the Gleason score of 7-10 and the T3-4), a meta-
regression approach was adopted (i.e. regression of the
selected predictor on the Log RR of the corresponding
outcome); the time delay in months for each considered
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trial between the duration of the short and the long
treatment arm was considered in the meta-regression
analysis as treatment predictor as well. Calculations
were accomplished using the Comprehensive Meta-
Analysis Software, version v. 2.0 (CMA, Biostat, Engle-
wood, NJ, USA).
Correlation
Potential correlations to test surrogacy between primary
and secondary end-points, were explored according to
regression between the calculated RRs and their logs for
each outcome.
Results
Selected trials
Twelve trials (7,811 patients) were identified (Figure 1)
[2-11,33-37]. Seven RCTs were excluded because HT
was administered in one arm only (4,387 patients)
[2-11,33], question already answered in a previous meta-
analysis [38]. Five RCTs were included in the meta-
analysis, all evaluable for BF (3,424 patients) [7,34-37].
According to the trial’ selection, the shorter approach
ranged from 3 to 6 months, while the longer from 8 to
36 months; trials characteristics are listed in Table 1.
Four were evaluable for CSS, OS, and three for LR and
DM [34-37]. Toxicity analysis was not performed
because data about toxicity were available only in two
studies. Median follow-up ranged from 3.7 to 10 years.
Three predictors were identified: median PSA (range
9.5-20.35), Gleason score 7-10 (range 27-55% of
patients/trial) and T3-4 (range 13-77% patients/trial).
Combined Analysis
With regard to the primary outcomes, the longer HT
significantly decreased biochemical failure over the
shorter HT with an absolute benefit of 10.1% (RR 1.32,
95% CI 1.09, 1.60, p = 0.004), corresponding to 9-10
patients to be treated for one to benefit, although with
significant heterogeneity (p = 0.003) (Table 2). A non
significant trend in the prostate-cancer specific survival
was found (RR 1.21, 95% CI 0.82, 1.79, p = 0.32) when
adopting a longer HT, without significant heterogeneity.
Concerning the secondary outcomes, the longer HT sig-
nificantly reduced both the risk of local recurrences (RR
1.87, 95% CI 1.22, 2.86, p = 0.004) and the risk of dis-
tant metastases (RR 1.77, 95% CI 1.16, 2.69, p = 0.007)
by 11.7% and 11.5%, without significant heterogeneity,
which translate into 9 patients to be treated for one to
benefit (Table 2). No significant differences in overall
survival were observed by comparing the two arms
(Table 2).
According to the performed meta-regression analysis,
none of the considered negative predictors significantly
affected outcome. Conversely, the treatment predictor
(the time delay) significantly correlates with all explored
outcomes (Table 3).
Correlation Analysis
The correlation analysis was performed in the 4 RCTs,
in which BF could be considered as a potential surrogate
endpoint [34-36]. The regression between the RR of BF
and the Log of CSS (p = 0.005) was statistically signifi-
cant. The regression between the RR of OS and the Log
of BF and CSS was not significant (p = 0.052 and p =
0.16, respectively). The regression of the RR of DM and
the Log of BF and CSS was statistically significant (p =
0.029 and (p = 0.041, respectively). The regression of
the RR of LR and the Log of BF was statistically signifi-
cant (p = 0.049).
Discussion
Although the number of studies is small to produce reli-
able estimates, the data presented herein strengthen the
role of the hormone-therapy duration in patients candi-
dates to receive androgen suppression in association
with radiotherapy for locally advanced prostate cancer
(Table 2 Figures 2, 3).
Hormonal suppression in patients affected by locally
advanced prostate cancer candidates to receive exclusive
radiotherapy is able to improve outcome, as a series of
trials recently demonstrated; according to the results of
our previous meta-analysis, hormonal suppression plus
radiotherapy significantly decreases recurrence and mor-
tality of patients with localized prostate cancer. The
magnitude of this survival benefit ranges from 4.9% to
5.5% for OS and CSS, respectively, which translates into
20 and 18 NNT. Local and distant relapse were signifi-
cantly decreased by hormonal treatment, by 36% and
28%, without significantly affect toxicity [38].
5 RCTs included in the 
meta-analysis (3,424 pts)
12 Potential RCTs identified
(7,811 pts)
7 RCTs excluded because
of exclusion criteria 
(HT in one arm only)
(4,387 pts)*
5 RCTs evaluable for BF 
(3,424 pts)
Primary Outcomes Secondary Outcomes
4 RCTs evaluable for CSS 
(3,128 pts)
Data not available for 
1 RCT (296 pts)
3 RCTs evaluable for LR and DM
(2,852 pts)
Data not available for 
2 RCTs (572 pts)
4 RCTs evaluable for OS
(3,128 pts)
Data not available for 
1 RCT (296 pts)
Figure 1 Outline of the search - Flow diagram. RCTs: randomized
clinical trials; pts: patients; HT: hormone therapy; BF: biochemical
failure; OS: overall survival; CSS: cancer specific survival; LR: local
recurrences; DM: distant metastases.
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Although the use of adjuvant hormonal therapy has
been shown in randomized trials to improve outcomes,
two issues still need to be clarified: 1) the optimal hor-
mone therapy duration and 2) the impact of the radia-
tion dose on outcome and local control. Within this
context, the current meta-analysis was aimed to assess if
difference exist between a shorter and longer androgen
suppression, according to the trialist’ definition. The
pooled results of the considered trials show that a
longer treatment approach improves all outcomes when
compared to a shorter one (Table 2 Figure 2, 3). In par-
ticular, BF is significantly reduced when hormone-ther-
apy is administered in a longer fashion, with an overall
absolute difference of 10.1%, which corresponds to only
9-10 patients needed to be treated for one to benefit
(Table 2). Although the meta-regression analysis could
be not valid given the small number of gathered trials,
the benefits present across all outcomes are provided in
favour of a longer strategy, regardless of any of the
selected negative predictors, suggesting an overall effect
independent by any clinico-pathological feature. Conver-
sely to the these predictors, the lenght of treatment
seems to significantly affect all outcomes, suggesting the
even more independent value of a longer approach
(Table 3). Although this interpretation should be sof-
tened, given the limitations related to a meta-regression
analysis, a further individual patient data meta-analysis
could eventually clarify if a particular subset of patients
would better benefit of such approach. Moreover, these
conclusion should be driven only when an homogenous
risk classes classification was likely to be prospectively
adopted in all analyzed trials. Indeed, the significant het-
erogeneity in the selected primary outcome can easily
reflect that the magnitude of the reported benefit is dif-
ferent across trials, and this can likely be a clear effect
of the different patient’ selection.
The adopted meta-analytic method did not allow to
extract patients’ subgroups data from those trials where
either low, intermediate and high risk patients were
accrued together. For example, no advantage for longer
duration was found in those trials enrolling low risk
Table 1 Trials’ Characteristics
Authors Pts Dose RT (Gy) Arms (mo.) Median
F.U.
End-Points Median
PSA (ng/mL)
N° of pts (%)
Primary Secondary Gleason
Score 7-10
T3-T4
Laverdiere
et al
148
148
64 5 (AS)
10 (AS)
3.7 yrs BDFS, CDFS - 11.9
12.7
82 (27.6) 40 (13.4)
Crook et al 177
184
66 3 (GF)
8 (GF)
79 mo. OS, CSS, DFS - 8.9
10.1
178 (49.3) 48 (13.2)
Horwitz
et al
763
758
65-70 4 (GF)
24 (GF)
10 yrs DFS OS, BF, DMF 20.8
19.8
838 (55.1) 829 (54.5)
Bolla
et al
483
487
70 6 (CAB)
36 (CAB)
5.2 yrs OS, CPFS, DS, BPFS - 18.8
18.8
479 (49.3) 754 (77.7)
Armstrong
et al
127
134
50-74 4 (CAB)
8 (CAB)
102 mo. BF OS, CSS 17.0
13.6
153 (55.4) 159 (57.6)
Pts: patients; RT: radiotherapy; Gy: gray; mo.: months; F.U.: follow-up; PSA: serum prostate-specific antigen; N°: number; AS: androgen suppression; yrs: years;
BDFS: biochemical disease free survival; CDFS: clinical disease free survival; GF: goserelin + flutamide; OS: overall survival; CSS: cancer specific survival; DFS:
disease free survival; BF: biochemical failure; DMF: distant metastases failure; CAB: complete androgen blockade; CPFS: clinical progression free survival; BPFS:
biochemical progression free survival: BF: biochemical failure.
Table 2 Combined efficacy results
Outcomes Pts
(RCTs)
RR (95% CI) p-value Het.
(p)
AD
(%)
NNT
BF 3,424 (5) 1.32 (1.09,
1.60)
0.004 0.003 10.1 9-10
CSS 3,128 (4) 1.21 (0.82,
1.79)
0.32 0.09 - -
OS 3,128 (4) 1.09 (0.92,
1.28)
0.28 0.15 - -
DM 2,852 (3) 1.77 (1.16,
2.69)
0.007 0.06 11.5 9
LR 2,852 (3) 1.87 (1.22,
2.86)
0.004 0.10 11.7 9
Pts: patients; RCTs: randomized clinical trials; RR: relative risk; CI: confidence
intervals; Het.: heterogeneity; p: p-value; AD: absolute difference; NNT: number
needed to treat; BF: biochemical failure; CSS: cancer specific survival; OS:
overall survival: LR: local relapse; DM: distant metastases.
Table 3 Meta-regression Analysis
Outcome Predictor p-value
Log RR Median PSA G 7-10 T3-4 Time Delay
BF 0.34 0.35 0.43 0.0003
CSS 0.11 0.81 0.19 0.03
OS 0.50 0.15 0.06 0.03
LR 0.21 0.70 0.18 0.03
DM 0.81 0.23 0.63 0.02
RR: relative risk; G: Gleason score; T: t-size; Time delay: time interval between
the short and the long hormonal treatment duration; BF: biochemical failure;
CSS: cancer specific survival; OS: overall survival: LR: local relapse; DM: distant
metastases.
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patients [7,39] (Figure 2, 3). Conversely, the positive
effect of long term hormonal duration can be partially
driven by the inclusion of those 2 trials including
patients with node-positive disease [34,36]. So, we are
not able to actually exclude a ‘carry-over’ effect due to
the inclusion of such trials with these characteristics.
The mixture of such confounders (such as different cut-
offs in the Gleason score) in trial selection does not
allow to derive clear and definitive conclusions.
Nevertheless, even taking into account all the drawbacks
in correlation and meta-regression estimations of cumulat-
ing few trials, the absolute difference in favour of the
longer HT (and the lower NNT) strongly justifies a pro-
longed treatment strategy. Moreover, the meta-regression
analysis did also show a significant correlation between
the length of the longer strategy and the effect in the
reduction of BF, LR and DM and the improvement of CSS
(Table 3 Figure 2). The latest conclusion allows to care-
fully speculate upon a ‘treat-until-progression’ strategy, at
least in the context of a randomized trial.
Recent reports suggest that the risk of cardio meta-
bolic problems with long-term castration deprivation
therapy could counteract the benefits of hormone ther-
apy, although this has also been questioned. Long term
androgen suppression can reduce the quality of life and
increase the risk of fatal myocardial infarction, fractures,
and the development of a metabolic syndrome. In the
context of neoadjuvant approaches, it has been recently
reported that hormone-therapy is associated with a sig-
nificant increase of all-cause mortality in those patients
with a cardiac comorbidity, but not in those who did
not show any history of cardiovascular disease [40]. This
represent a crucial step-forward in the selection of those
patient who could be considered as appropriate candi-
dates for a longer hormonal suppression.
The radiotherapy component of the combined treat-
ment is crucial: cancer-specific and overall mortality
rates at 10 years are significantly lower with the com-
bined treatment in respect to androgen suppression
alone. Moreover, the survival benefit seem to depend on
the duration of homone-therapy, and was also reported
by the Early Prostate Cancer Programme using adjuvant
antiandrogen treatment as well. In studies with short or
intermediate androgen deprivation of, survival prolonga-
tion has only been reported in subgroups.
At the start of these trials, the standard radiation dose
to the prostate was 70 Gy or less. With the advent of
intensity-modulated and image-guided radiotherapy
techniques, radiation doses of 78 Gy or higher are now
possible, and randomised studies have shown that bio-
chemical relapse-free survival improves with high radia-
tion doses. As a consequence, the overall survival
benefit might further increase further with higher safely
radiation doses [41-44]. Clearly, open issues remain
whether the duration of the hormonal suppression
could eventually affect the outcome when radiation
therapy is administered with higher dosages, and what
should be irradiated (prostate or the whole pelvis).
The general shared consensus is that high risk patients
would better benefit from two to three years of adjuvant
androgen deprivation, while those with intermediate’ risk
prostate cancer from six months of adjuvant androgen
deprivation plus radiotherapy delivered with a dose lower
or equal to 70Gy (for doses higher than 70 Gy the appro-
priate duration of adjuvant androgen deprivation is still
unknown) [16,17]. According to the trial recently published
by Bolla et al, the effect of short-term and long-term
androgen suppression upon five-year mortality is likely to
Reference Outcome Risk Ratio and 95% CI 
Crook et al  IJRBP 2008 CSS
Armstrong et al IJRBP 2010 CSS
Horwitz et al JCO 2008 CSS
Bolla et al NEJM 2009 CSS
0.5 1 2
Favours ST Favours LT
Armstrong et al IJRBP 2010 BF
Lavardiere et al JU 2004 BF
Horwitz et al JCO 2008 BF
Crook et al  IJRBP 2008 BF
Bolla et al NEJM 2009 BF
Figure 2 Combined Results - Primary Outcomes (BF, CSS). CI:
confidence intervals; BF: biochemical failure; CSS: cancer specific
survival; ST: shorter therapy: LT: longer therapy.
Reference Outcome Risk Ratio and 95% CI 
0.5 1 2
Favours ST Favours LT
Crook et al  IJRBP 2008 OS
Armstrong et al IJRBP 2010 OS
Horwitz et al JCO 2008 OS
Bolla et al NEJM 2009 OS
Crook et al  IJRBP 2008 DM
Horwitz et al JCO 2008 DM
Bolla et al NEJM 2009 DM
Crook et al  IJRBP 2008 LR
Horwitz et al JCO 2008 LR
Bolla et al NEJM 2009 LR
Figure 3 Combined Results - Secondary Outcomes (OS, DM,
LR). CI: confidence intervals; OS: overall survival; DM: distant
metastases; LR: local recurrences; ST: shorter therapy: LT: longer
therapy.
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be maintained at ten years [39,45], whereas the short-term
benefit may actually be no longer effective. The intriguing
factor that can help in the daily decision between one strat-
egy over the other is the relative weight of adverse events
and the adverse effects on quality of life between the two
groups of patients; indeed, although no significant differ-
ence in the overall quality of life did emerge between the
two groups in the Bolla et al trial (p = 0.37), a clinically
meaningful difference was present for hot flushes, sexual
interest, and sexual activity [34]. Unfortunately, our analy-
sis could investigate neither the pooled toxicities nor the
quality of life data into a cumulative fashion, given the lack
of a complete reporting in the original trials.
Although the treatment duration seems to significantly
impact upon outcome, it should be acknowledged that
other factors may have a critical role, or may be more
important: indeed, in the recent update of the Crook
et al study, the more relevant weight for benefit seems
related more to the early biochemical response to hor-
monal treatment before radiotherapy, rather than its
overall duration [46]. For these reasons, a critical view
of all data as shown in our analysis (taking into account
all the limitations related to the adopted approach and
methodology) is recommended.
Conclusions
Taking into account the current data available in litera-
ture, and the results reported herein, the significant dif-
ferences in outcome in favour of a longer hormonal
treatment duration do support the adoption of such a
strategy for patients affected by locally advanced pros-
tate cancer, although several limitations should be con-
sidered given the small number of trials included.
Nevertheless, a careful patient selection upon the pre-
sence/absence of cardiovascular and/or metabolic
comorbidities should be adopted, in order to avoid sig-
nifican late-term toxicities. On the contrary, a wide
adoption of a longer administration regardless of the
risk stratification (notwithstanding the results of the
meta-regression analysis) seems in some way not
enough mature, in absence of more reliable data coming
from an individual patient data meta-analysis.
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